Acorda plans NDA for inhaled Parkinson’s drug after touting long-term safety data

Acorda Therapeutics (NSDQ:ACOR) touted data from 2 ongoing, long-term safety studies of its inhaled Parkinson’s therapy. The trials showed no difference in pulmonary function between the group receiving CVT-301, the inhaled formulation of Parkinson’s drug levodopa, and the control group.

The investigational drug is being studied as a therapy for people with Parkinson’s disease experiencing “off” periods, or a re-emergence of symptoms. The Ardsley, N.Y.-based company said the 12-month safety results are consistent with data from Phase IIb and III clinical evaluations.

Get the full story at our sister site, Drug Delivery Business News.

The post Acorda plans NDA for inhaled Parkinson’s drug after touting long-term safety data appeared first on MassDevice.

from MassDevice http://ift.tt/2oeENah